TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26185909

Group type: EXPERIMENTAL
Intervention: Thalidomide 1.5 to 2.5 mg/kg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thalidomide (for nonresponders switched from placebo)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 26
Study: 23306448

Group type: EXPERIMENTAL
Intervention: tDCS(a) + AT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: tDCS(c) + AT
Number of subjects: 18
Study: 21040412

Group type: EXPERIMENTAL
Intervention: IGF-I treatment (50 μg/kg, twice daily for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (saline injections)
Number of subjects: 16
Study: 18976450

Group type: EXPERIMENTAL
Intervention: Arm A (docetaxel 70 mg/m2 on day 1 and gemcitabine 900 mg/m2 on days 3-8, every 3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm B (gemcitabine 900 mg/m2 on days 1 and 8, and docetaxel 70 mg/m2 on day 8, every 3 weeks)
Number of subjects: 0
Study: 17002625

Group type: EXPERIMENTAL
Intervention: PCT FFP
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control FFP
Number of subjects: 35
Study: 14601230

Group type: EXPERIMENTAL
Intervention: Hyalofill-F plus compression bandaging
Number of subjects: 20
Study: 11113492

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (0.3 mg administered 3.5 h after nicotine withdrawal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8730247

Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment with different drugs
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Patients without electron microscopic features of infiltration
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Patients with bacteria deeply embedded into the gastric mucosa
Number of subjects: 182

Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 182
Study: 1305469

Group type: EXPERIMENTAL
Intervention: Attenuated strain of influenza A virus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 3891357

Group type: EXPERIMENTAL
Intervention: CMF + tamoxifen (T)
Number of subjects: 263

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 263
Study: 31118740

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (six 2-hr group sessions over 6 months)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 443
Study: 29252110

Group type: EXPERIMENTAL
Intervention: Internet use
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Internet access frequency
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Device used for Internet access
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Willingness to use videoconferencing
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Comfort with new devices (with in-person assistance)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Comfort with new devices (on your own)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Association between Internet use and comfort with new technology devices
Number of subjects: 592
Study: 27632268

Group type: EXPERIMENTAL
Intervention: Laser-microtextured implants
Number of subjects: 17

Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 17
Study: 25371457

Group type: EXPERIMENTAL
Intervention: 28 mm ceramic articulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: 32 mm ceramic articulation
Number of subjects: 120
Study: 23101262

Group type: EXPERIMENTAL
Intervention: Liniment cycloferon included in combined therapy
Number of subjects: 30
Study: 20486273

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 18588706

Group type: EXPERIMENTAL
Intervention: Community, school, and family-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (5 schools)
Number of subjects: 0
Study: 15807808

Group type: EXPERIMENTAL
Intervention: Corneometer CM-A (CM820)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Corneometer CM-B (CM820)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Corneometer CM-C (CM810)
Number of subjects: 53
Study: 12204802

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (A10)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day (S20)
Number of subjects: 391
Study: 10344043

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg
Number of subjects: 88

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study: 7661269

Group type: EXPERIMENTAL
Intervention: Group 1 (immediate full hyperextension)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Group 2 (control, no immediate full hyperextension)
Number of subjects: 174
Study: 8452322

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg per day
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 3539796

Group type: EXPERIMENTAL
Intervention: Felodipine (acute oral administration)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Felodipine (1 week treatment)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Felodipine (6 weeks treatment)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Felodipine (withdrawal of treatment)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Felodipine (ambulatory intra‐arterial data)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 9
Study: 29656273

Group type: EXPERIMENTAL
Intervention: Telerehabilitation mediated assessment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional in‐person method
Number of subjects: 59
Study: 27471837

Group type: EXPERIMENTAL
Intervention: Pradigastat
Number of subjects: 47

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 47
Study: 23603054

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 115
Study: 22672214

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser photocoagulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Liquid paraffin plus antiseptic cream
Number of subjects: 80
Study: 20692757

Group type: EXPERIMENTAL
Intervention: Risk factors associated with perpetrating forced sex
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Earning income for less than 12 months a year
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Visiting the wine shop with friends
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: STD symptoms
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Perpetration of physical violence
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Having 3 or more close friends
Number of subjects: 1499
Study: 18446692

Group type: EXPERIMENTAL
Intervention: Slow escalation of rivastigmine
Number of subjects: 429

Group type: COMPARATOR
Intervention: Fast escalation of rivastigmine
Number of subjects: 429
Study: 15695147

Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co-morbidities (diabetes and coronary artery disease)
Number of subjects: 0
Study: 12881334

Group type: EXPERIMENTAL
Intervention: IOLMaster biometry
Number of subjects: 100

Group type: COMPARATOR
Intervention: Applanation ultrasonography
Number of subjects: 100
Study: 9788519

Group type: EXPERIMENTAL
Intervention: Specimen ratio of 0.5
Number of subjects: 6

Group type: COMPARATOR
Intervention: Specimen ratio evaluation in a water dilution study
Number of subjects: 6
Study: 7972904

Group type: EXPERIMENTAL
Intervention: Irradiated small bowel volume below 77 cm3
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Irradiated small bowel volume over 328 cm3
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Low anterior resection
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Overall small bowel obstruction
Number of subjects: 203
Study: 2743665

Group type: EXPERIMENTAL
Intervention: Continuous passive motion machine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 50
Study: 4560057

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan with a peripheral decarboxylase inhibitor
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31213409

Group type: EXPERIMENTAL
Intervention: Eczema children
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 6
Study: 31204115

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (paclitaxel and iopromide)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 208
Study: 28860894

Group type: EXPERIMENTAL
Intervention: 28 mL of 370 mgI/mL iodinated contrast media at a flow rate of 3.5 mL/s
Number of subjects: 104

Group type: COMPARATOR
Intervention: 40 mL of 370 mgI/mL iodinated contrast media at a flow rate of 5 mL/s
Number of subjects: 104
Study: 26364081

Group type: COMPARATOR
Intervention: Natural Cycle (NC FET group)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: hMG FET group (hormonally stimulated cycle)
Number of subjects: 410
Study: 23127578

Group type: EXPERIMENTAL
Intervention: Learning Module (LM, n=47)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sham Module (SM, n=40)
Number of subjects: 87
Study: 21559859

Group type: EXPERIMENTAL
Intervention: Surgical intervention (not specified in detail)
Number of subjects: 182
Study: 18076751

Group type: EXPERIMENTAL
Intervention: Small-incision cholecystectomy (SIC)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Conventional open technique (conversion from SIC or LC)
Number of subjects: 257
Study: 16563715

Group type: EXPERIMENTAL
Intervention: 0.2 mg of salbutamol
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (after 6 and 12 weeks of therapy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Neutrophilic inflammation (measured by serum concentration of myeloperoxidase)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Clinical severity indicators and blood markers (including daily PEF variation, rescue bronchodilator use, severity of asthmatic symptoms, blood eosinophil count, serum eosinophilic cationic protein, and eosinophilic protein X concentrations)
Number of subjects: 101
Study: 14626623

Group type: EXPERIMENTAL
Intervention: Evidence-based practices in health promotion
Number of subjects: 0
Study: 10709815

Group type: EXPERIMENTAL
Intervention: On-line visual analysis during surgery
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Off-line visual analysis in laboratory
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Computer analysis
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Statistical analysis for SEF variability and 8-15 Hz power variability and asymmetry
Number of subjects: 104
Study: 9519501

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg o.d.
Number of subjects: 129

Group type: COMPARATOR
Intervention: Atenolol 100 mg o.d.
Number of subjects: 129
Study: 8480901

Group type: EXPERIMENTAL
Intervention: Propofol/Fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 60
Study: 3481149

Group type: EXPERIMENTAL
Intervention: Grenz ray therapy
Number of subjects: 0
Study: 30158217

Group type: EXPERIMENTAL
Intervention: PrenaBelt
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-PrenaBelt
Number of subjects: 20
Study: 27573600

Group type: EXPERIMENTAL
Intervention: Alirocumab (ALI) 75/150mg every 2 weeks (Q2W)
Number of subjects: 4629

Group type: EXPERIMENTAL
Intervention: Alirocumab (ALI) 150mg Q2W
Number of subjects: 4629

Group type: EXPERIMENTAL
Intervention: Alirocumab (ALI)
Number of subjects: 4629
Study: 25569680

Group type: EXPERIMENTAL
Intervention: Foley balloon standard placement
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Foley balloon immediate removal
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard placement)
Number of subjects: 79
Study: 23546632

Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablet (FZHYT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 20887348

Group type: EXPERIMENTAL
Intervention: Long-acting ß2-agonist and inhaled glucocorticoid (fluticasone propionate) for 3 months (group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Long-acting ß2-agonist (salmeterol) for 3 months (group 1)
Number of subjects: 40
Study: 18424594

Group type: EXPERIMENTAL
Intervention: L-alpha-glycerophosphocholine (L-alpha) added to vegetarian lasagna
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (100 mg) added to vegetarian lasagna
Number of subjects: 13
Study: 16382035

Group type: EXPERIMENTAL
Intervention: Albendazole at 15 mg/kg/day plus dexamethasone for 8 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Albendazole at 30 mg/kg/day plus dexamethasone for 8 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Albendazole (any dose)
Number of subjects: 36
Study: 12794555

Group type: EXPERIMENTAL
Intervention: Needle exchange program (NEP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Pharmacy Sales (training in how to purchase needles and syringes)
Number of subjects: 600
Study: 10391534

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) with 0.625 mg/day of conjugated equine estrogen (CEE) or 50 microg/day of 17‐beta‐Estradiol in transdermal therapeutic systems (TTS), plus 5 mg/day of medroxyprogesterone acetate for those with natural menopause for the last 12 days of therapy.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (non-treated) for surgical menopause (n=77)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (non-treated) for spontaneous menopause (n=53)
Number of subjects: 154
Study: 8874325

Group type: EXPERIMENTAL
Intervention: High-dose interferon alfa-2b (IFN alpha 2b) treatment
Number of subjects: 280

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 280
Study: 2005554

Group type: EXPERIMENTAL
Intervention: Occucoat (2% hydroxypropylmethyl‐cellulose) removed from the anterior chamber
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Occucoat (2% hydroxypropylmethyl‐cellulose) retained
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Viscoat (sodium hyaluronate‐chondroitin sulfate) removed
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Viscoat (sodium hyaluronate‐chondroitin sulfate) retained
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate) removed
Number of subjects: 114
Study: 6213195

Group type: EXPERIMENTAL
Intervention: Piperacillin (2.0 g) with 1.0 g probenecid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 X 10(6) U) with 1.0 g probenecid
Number of subjects: 120
Study: 31607467

Group type: EXPERIMENTAL
Intervention: Continuous improvement strategies related to sexual health in intervention clusters
Number of subjects: 34878

Group type: COMPARATOR
Intervention: Usual care in control clusters
Number of subjects: 34878
Study: 29954736

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Education and text message reminders
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Education and mailed sunscreen
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Education, text message reminders, and mailed sunscreen
Number of subjects: 357
Study: 26328620

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing combined with Standard Care (MISC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard Care only (SC)
Number of subjects: 37
Study: 25112083

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at eight-neck-occiput points (Neck 1-4 points, Occiput 1-4 points), treatment once a day for 4 weeks, 5 treatments a week, using dense-dispersion wave for 30 minutes.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine acupoints (Lianquan (CV 23), Futu (LI 18), Tongli (HT 5), Hegu (LI 4), and others), treatment once a day for 4 weeks, 5 treatments a week, using dense-dispersion wave for 30 minutes.
Number of subjects: 72
Study: 20434175

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 41
Study: 19593220

Group type: EXPERIMENTAL
Intervention: Light Bat (LB = 9.6 oz)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Normal Bat (NB = 31.5 oz)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Heavy Bat (HB = 55.2 oz)
Number of subjects: 19
Study: 16430409

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cuffed Tracheal Tube (TT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Uncuffed Tracheal Tube (TT)
Number of subjects: 45
Study: 12777270

Group type: EXPERIMENTAL
Intervention: High-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10694522

Group type: EXPERIMENTAL
Intervention: Transcatheter closure of atrial septal defects under echocardiographic guidance without fluoroscopy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional procedure (control group)
Number of subjects: 22
Study: 9176846

Group type: EXPERIMENTAL
Intervention: Standard prednisone regimens
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Initial responders (complete remission)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Initial relapsers (frequent and infrequent)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Unremitting proteinuria during the initial 8 weeks of treatment
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Continued proteinuria during the initial 8 weeks
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Overall outcome
Number of subjects: 389
Study: 1585795

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) with Cimetidine (CIM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC) without Cimetidine (CIM)
Number of subjects: 8
Study: 3898911

Group type: EXPERIMENTAL
Intervention: 5% lidocaine-prilocaine cream (EMLA) applied for 20 min or longer
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 30203076

Group type: EXPERIMENTAL
Intervention: E‐cigarette use
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: No product use
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tobacco cigarette use
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dual use
Number of subjects: 48
Study: 28700653

Group type: EXPERIMENTAL
Intervention: Bradykinin (1-8)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Bradykinin (1-7)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Hyp3-bradykinin (1-7)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Hyp3-bradykinin (1-8) in losartan group
Number of subjects: 243
Study: 25592314

Group type: EXPERIMENTAL
Intervention: Group-based weight management intervention targeting diet and physical activity plus usual care
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 23595264

Group type: EXPERIMENTAL
Intervention: Primary care-based and community partnered obesity intervention
Number of subjects: 0
Study: 22042116

Group type: COMPARATOR
Intervention: Intravenous tramadol and intrapleural saline solution (Group A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone and intrapleural 0.33% ropivacaine (Group B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous dipyrone and intrapleural 0.5% ropivacaine (Group C)
Number of subjects: 24
Study: 20024764

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to prevent HIV transmission
Number of subjects: 116
Study: 16686840

Group type: EXPERIMENTAL
Intervention: PCT (photochemical treatment with amotosalen HCl and ultraviolet A light)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference (untreated apheresis PLTs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference
Number of subjects: 32
Study: 15043516

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (dyspeptic patients)
Number of subjects: 45
Study: 11092108

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg once daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Bisoprolol plus nifedipine 20 mg twice daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Bisoprolol plus amlodipine 5 mg once daily
Number of subjects: 198
Study: 9557088

Group type: EXPERIMENTAL
Intervention: Four-hour hemodialysis
Number of subjects: 23

Group type: COMPARATOR
Intervention: Chronic uremic patients (pre-dialysis)
Number of subjects: 23
Study: 8454139

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 3% NaCl solution
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 50% glucose/water solution
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pure alcohol
Number of subjects: 200
Study: 3749811

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 87

Group type: COMPARATOR
Intervention: High-dose liquid antacid
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer (subgroup)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Prepyloric ulcer (subgroup)
Number of subjects: 87
Study: 29356271

Group type: EXPERIMENTAL
Intervention: Regenerative serum (Matricium®) applied twice daily for 2 months after fractional laser procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 2 months after fractional laser procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regenerative serum (Matricium®)
Number of subjects: 0
Study: 26807488

Group type: EXPERIMENTAL
Intervention: First-line platinum/taxane combination chemotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control cohort of high-grade serous ovarian cancer (HGSOC)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Complete cytoreduction
Number of subjects: 145